Are you the publisher? Claim or contact us about this channel


Embed this content in your HTML

Search

Report adult content:

click to rate:

Account: (login)

More Channels


Showcase


Channel Catalog


Channel Description:

Visit One News Page for Health Insurance news from around the world, aggregated from leading sources including newswires, newspapers and broadcast media. Search millions of archived news headlines. This feed provides the Health Insurance news headlines.

older | 1 | .... | 940 | 941 | (Page 942) | 943 | 944 | .... | 952 | newer

    0 0

    Dublin, Dec. 11, 2018 (GLOBE NEWSWIRE) -- The "Medical Imaging Instrumentation: Global Markets and Technologies Through 2022" report has been added to *ResearchAndMarkets.com's* offering.The scope of this report is broad and covers various types of products available in the medical imaging instruments market and potential application sectors across various industries. The medical imaging instruments market is broken down into product types such as X-ray systems, ultrasound devices, MRI, computed tomography and nuclear imaging. Revenue forecasts from 2017 to 2022 are given for each product type, technologies, application and end users with an estimated value derived from the revenue of manufacturers' total revenues.

    The report also includes a discussion of the major players across each regional medical imaging instrument market. It explains the major drivers and regional dynamics of the global medical imaging instruments market and current trends within the industry. The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors in the global medical imaging instruments market.Due to the prevalence of chronic diseases coupled with the increasing geriatric population and the number of road accidents, stronger demand for better imaging has emerged.

    Chronic diseases such as cancer, strokes, neurodegenerative diseases, COPD (chronic obstructive pulmonary disease), cardiovascular diseases and others require imaging of body parts for proper diagnosis of the disease. Such high instances of chronic diseases require improved and advanced imaging technologies such as MRI, ultrasound, and others.Also, the number of road accidents calls for imaging technologies in cases of major and minor fractures. According to the World Health Organization (Switzerland), nearly 1.24 million people throughout the world die each year due to road traffic crashes that equates to ~3,400 deaths per day. Imaging instruments find huge application in cases of fractures.

    Factors such as the prevalence of chronic diseases and an increasing geriatric population, coupled with the increasing demand for 3D medical imaging equipment, are also providing traction to the global medical imaging instruments market.

    Companies are focusing on the continuous development of products that support novel imaging technologies such as colored and 3D imaging due to their rising demand. Surging investments on technological advancements for increasing resolution and pixel capabilities, wider disease detection capabilities and more advanced software can be observed in the market.

    For instance, in 2017, Royal Philips (Netherlands) announced a new MRI system, MR Prodiva 1.5T, with enhanced clinical performance, workflow, and capability of 2D and 3D scans. Similarly, launched in November 2017 by NPL (National Physical Laboratory), 3D OrbiSIMS is a molecular imaging instrument used to explore potentials under cell biology and drug discovery.

    The imaging technologies are used across various end users including hospitals, diagnostic centers, and research centers. In hospitals, the imaging instruments are used for imaging body parts in cases of chronic diseases or accidents. In diagnostic centers, the imaging instruments are widely adopted for diagnosing a particular body part or the whole body. The imaging instruments are used for molecular imaging in the research centers for drug discovery purposes.

    The report provides an analysis based on each product type segment, which includes X-ray systems, magnetic resource imaging equipment/instruments, computed tomography scanners, ultrasound systems, and nuclear imaging equipment/instruments.

    *Key Topics Covered**Chapter 1 Introduction*

    · Study Goals and Objectives
    · Reasons for Doing This Study
    · Scope of Report
    · Methodology
    · Geographic Breakdown
    · Analyst's Credentials
    · Custom Research
    · Related Reports

    *Chapter 2 Summary and Highlights*

    *Chapter 3 Overview*

    · Introduction
    · Regulations
    · United States
    · Europe
    · India
    · Australia
    · China
    · Market Potential
    · Industry Growth Drivers
    · Image-based Invasive and Noninvasive Procedures
    · Increasing Prevalence of Chronic Diseases and Rising Investments
    · Drug Discovery and Other R&D Activities
    · Increased Demand for 3D Medical Imaging Equipment
    · Increasing Geriatric Population across the Globe
    · Surging Adoption of Cloud Computing in Medical Imaging

    *Chapter 4 Medical Imaging Equipment/Instruments by Product Type*

    · X-ray Equipment/Instruments
    · Advantages of X-ray Machines
    · New Product Launches
    · Stationary X-ray Equipment/Instruments
    · Portable X-ray Equipment/Instruments
    · MRI Equipment/Instruments
    · MRI Equipment in Medical Applications
    · New Product Launches
    · Closed MRI Equipment/Instruments
    · Open MRI Equipment/Instruments
    · CT Scanners
    · CT Scanners in Medical Applications
    · Stationary CT Scans
    · Advantages of Mobile CT Scanners
    · New Product Launches
    · Ultrasound Equipment/Instruments
    · Cart/Trolley-Based Ultrasound Systems
    · Compact/Portable Ultrasound Equipment/Instruments
    · Nuclear Imaging Equipment/Instruments
    · SPECT Scanners

    *Chapter 5 Medical Imaging Equipment/Instruments by Technology*

    · X-ray Equipment/Instruments
    · Analog X-ray Equipment/Instruments
    · Digital Radiography
    · Computed Radiography
    · MRI Equipment/Instruments
    · Technological Advancements
    · Low-Field Strength MRI
    · Medium-Field Strength MRI
    · High-Field Strength MRI
    · CT Scanners
    · Low-Slice CT
    · Medium-Slice CT
    · High-Slice CT
    · Ultrasound Equipment/Instruments
    · Market Drivers
    · Technological Advancements
    · 2D Ultrasound
    · 3D and 4D Ultrasound
    · Doppler
    · High Intensity Frequency Ultrasound (HIFU)
    · Lithotripsy
    · Nuclear Imaging Equipment
    · SPECT Scanners
    · PET Scanners

    *Chapter 6 Medical Imaging Equipment/Instruments by Application*

    · X-ray Imaging Equipment/Instruments
    · General Radiography
    · Dental
    · Mammography
    · MRI Equipment/Instruments
    · Brain and Neurological MRI
    · Spine and Musculoskeletal MRI
    · Vascular MRI
    · Pelvic and Abdominal MRI
    · Breast MRI
    · Cardiac MRI
    · Ultrasound Equipment/Instruments
    · Radiology/General Imaging
    · Obstetrics/Gynecology (OB/GYN)
    · Cardiology
    · Vascular
    · Urology
    · Other Applications
    · CT Scanners
    · Cardiology
    · Oncology
    · Neurology
    · Other Applications
    · Nuclear Imaging Equipment/Instruments
    · Cardiology
    · Oncology
    · Neurology
    · Other Applications

    *Chapter 7 Medical Imaging Equipment/Instruments by End User*

    · Hospitals
    · Diagnostic Centers
    · Transition of Healthcare Service from Service for Fee to Value Based Care Models
    · High Penetration of Health Insurance
    · Trends in Diagnostics Imaging Market
    · Research Centers
    · Increasing R&D Spending
    · Research Areas of Biomedical Imaging Equipment/Instruments
    · Applications of Biophotonics and Biomedical Imaging in Research

    *Chapter 8 Medical Imaging Equipment/Instruments by Region*

    · North America
    · United States
    · Canada
    · Mexico
    · Europe
    · United Kingdom
    · France
    · Germany
    · Spain
    · Italy
    · Rest of Europe
    · Asia-Pacific
    · China
    · India
    · Japan
    · South Korea
    · Australia
    · Rest of Asia-Pacific
    · Rest of the World
    · Latin America
    · Middle East and Africa

    *Chapter 9 Medical Imaging Equipment/Instruments Industry Structure*

    · Raw Material Suppliers
    · Quality
    · Terms and Conditions
    · Cost-Effective Components
    · Manufacturing Process of Medical Imaging Instrument
    · Procurement of Raw Materials/Parts
    · Testing of Procured Products
    · Production of Remaining Parts/Raw Materials
    · Assembling
    · Testing of the Product
    · Distributors
    · End Users
    · Innovations in the Medical Imaging Equipment/Instruments Market

    *Chapter 10 Patent Analysis*

    · Japanese Patent Analysis
    · European Patent Analysis
    · U.S. Patent Analysis

    *Chapter 11 Company Profiles*

    · Adonis Medical Systems Pvt. Ltd.
    · AGFA Healthcare
    · Allengers
    · All Star X-Ray Inc.
    · Aurora Imaging Technology Inc.
    · Boston Scientific
    · Bruker Corp.
    · Canon Inc.
    · Carestream Health Inc.
    · Chison Medical Technologies Co. Ltd.
    · Cook Medical LLC
    · Elekta
    · Esaotespa
    · Fonar Corp.
    · Fujifilm Holdings Corp.
    · GE Healthcare
    · Hitachi Medical Corp.
    · Hologic Inc.
    · Icrco Inc.
    · Kalamed Gmbh Medical Systems
    · Konica Minolta Inc.
    · Medtronic PLC
    · Mindray
    · Neurologica Corp.
    · Neusoft Medical Systems
    · Philips Healthcare
    · Promed Group Co. Ltd.
    · Samsung Medison Co. Ltd.
    · Shenzhen Anasonic Bio-Medical Technology Co. Ltd.
    · Shimadzu Corp.
    · Siemens Healthcare
    · Varex Imaging Corp.

    For more information about this report visit https://www.researchandmarkets.com/research/gq66f5/medical_imaging?w=12

    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

    CONTACT:
    CONTACT: ResearchAndMarkets.com
    Laura Wood, Senior Press Manager
    press@researchandmarkets.com
    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900
    Related Topics: Medical Devices, Medical Imaging Reported by GlobeNewswire 10 hours ago.

    0 0

    Latest 2018 ez1095 ACA software is available for establishments to process in multiple offices in a network version. Test drive the 30 day no cost or obligation trial at halfpricesoft.com.

    PITTSBURGH (PRWEB) December 11, 2018

    Employers and tax professionals that need to process ACA (Affordable Care Act) forms 1095 in multiple offices, are accommodated with a network version for new 2018 ez1095 software from Halfpricesoft.com. ez1095 can process form 1095C, 1094C, 1095B and 1094B. It has also been approved by IRS to generate the efile documents that customers can upload to IRS for ACA form electronic filing.

    ez1095 software also allows customers to import data from external file and makes it easy to print ACA forms for recipients. Priced from just $195 per installation (cost differs with network and efile version). ez1095 can also support multiple company accounts on the same computer at no additional charge.

    “The latest version of ez1095 2018 software will easily accommodate multiple offices or computers when processing 1095 forms with the network version,” said Dr. Ge, the Founder of Halfpricesoft.com.

    Customers that are required to file Form 1095C, 1094C, 1095B and 1094B can download and try out this ACA software from halfpricsoft.com before purchasing with no obligation by visiting https://www.halfpricesoft.com/aca-1095/aca-1095-software.asp.

    The main features include but are not limited to :· Print ACA Form 1095-C, 1094-C, 1095-B and 1094-B on white paper for recipients and IRS with inkjet or laser printer.
    · PDF print 1095-C and 1095-B recipient copies
    · Efile version available at additional cost.
    · Support unlimited companies.
    · Support unlimited number of recipients.
    · Print unlimited number of 1095 and 1094 forms.
    · Fast data import feature
    · Print Form 1095 C: Employer-Provided Health Insurance Offer and Coverage Insurance
    · Print Form 1094 C: Transmittal of Employer-Provided Health Insurance Offer and Coverage Information Returns
    · Print Form 1095-B: Health Coverage
    · Print Form 1094-B: Transmittal of Health Coverage Information Return

    ez1095 software is compatible Windows 10, 8.1, 8, 7, and Vista. ez1095 software’s graphical interface leads customers step-by-step through setting up company, adding employees, add forms and print forms. Customers can also click form level help links to get more details regarding the software.

    To learn more about ez1095 ACA software, customers can visit http://www.halfpricesoft.com/aca-1095/aca-1095-software.asp

    About halfpricesoft.com
    Halfpricesoft.com is a leading provider of small business software, including online and desktop payroll software, online employee attendance tracking software, accounting software, in-house business and personal check printing software, W2, software, 1099 software, Accounting software, 1095 form software and ezACH direct deposit software. Software from halfpricesoft.com is trusted by thousands of customers and will help small business owners simplify payroll processing and streamline business management. Reported by PRWeb 9 hours ago.

    0 0

    Barack Obama urges people to sign up for health insurance before 2019 deadline Barack Obama promises "no memes" in a new video reminding people to sign up to healthcare coverage before a Sunday deadline. The former president has deployed a number of methods to try and grab attention, from... Reported by WorldNews 5 hours ago.

    0 0

    SOUTH PLAINFIELD, N.J., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Admera Health (www.admerahealth.com), an advanced molecular diagnostics company, announced today that its genetic testing services are now available as in-network benefits under CareFirst Blue Cross Blue Shield.  With over 3.2 million members, CareFirst offers the widest coverage and the largest network for medical, dental and vision insurance in Maryland, Washington D.C., and Northern Virginia. Their expansive network provides members with access to more than 1 million physicians, provider facilities, hospitals, and care centers. CareFirst has been providing health insurance to the region for over 75 years and is nationally recognized for its customer service for their members.Admera Health offers the most comprehensive pharmacogenomics testing services available, its PGxOne™ Plus test interrogates over 50 genes with coverage of over 200 genetic variants and provides  recommendations on over 300 drugs and over 300 medical conditions. Beyond Pharmacogenomics, Admera Health also offers LiquidGx™ (a liquid biopsy test), OncoGxOne™, and OncoGxSelect™ for tumor profiling to guide the selection of targeted therapies, cancer supportive care, and inherited cardiovascular diseases via its partnership with Health in Code.

    CareFirst beneficiaries will be able to receive genetic tests that utilize the latest genomic technologies to provide recommendations on medications based on a person’s genetic profile. “By utilizing CareFirst extensive list in-network partners, Admera Health will be able to help provide genetic tests to those patients who may not have access to them previously,” said Guanghui Hu, Ph.D., President and CEO of Admera Health.  “Admera Health believes molecular diagnostic and genetic tests should be available to all patients all around the world and by expanding in-network insurance coverage, this is one positive step to making this goal a reality”.

    About Admera Health

    Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improve the health and well-being of our global community through the direct delivery of personalized medically actionable results.

    Admera Health Contact:

    Brady Millican
    VP Business Development
    908-222-0533
    brady.millican@admerahealth.com Reported by GlobeNewswire 6 hours ago.

    0 0

    Dublin, Dec. 11, 2018 (GLOBE NEWSWIRE) -- The "Drug Adherence Enhancement Market: Devices and Applications, 2018-2030" report has been added to *ResearchAndMarkets.com's* offering.

    *Drug Adherence Enhancement Market: Devices and Applications, 2018-2030* features an extensive study of the current landscape and future outlook of the growing market for smart medication adherence devices that are either already commercialized or under development. This burgeoning field presently offers a lot of opportunities to innovation-driven start-ups and investors.

    Poor adherence to prescribed medications is a growing concern in the healthcare industry and is believed to be associated with negative health outcomes, inflated medical expenses, loss in productivity and, in certain cases, proves fatal as well. It has been estimated that, of the 4 billion annual prescriptions filled by the retailers in the US, approximately 50% are not taken by patients in accordance to physicians' instructions.

    According to the US Centers for Disease Control and Prevention (CDC), failure to comply to prescribed treatment regimens has been identified as the cause of 125,000 premature deaths, up to 69% of all rehospitalizations, and results in approximately USD 100-300 billion worth of avoidable annual healthcare spending. Further, the US pharmaceutical industry alone is estimated to suffer a loss of approximately USD 188 billion per year, due to low adherence to prescribed medications.

    Lack of compliance with therapy is particularly prevalent among elderly patients suffering from chronic clinical conditions, such as cardiovascular disorders, metabolic disorders (e.g., diabetes), neurological and central nervous system related disorders (e.g., multiple sclerosis and Parkinson's disease) and respiratory disorders (e.g., asthma and chronic obstructive pulmonary disease). It is estimated that overall cost of treatment for non-adherent patients is at least twice as high as patients who adhere to recommended therapy regimens.

    Studies have demonstrated that every one percent improvement in medication adherence can help the US healthcare industry save up to USD 2 billion, resulting in an increase in pharmaceutical revenues by ~USD 4 billion. As a result, several strategies have been/are being developed by pharmaceutical developers and healthcare providers to improve medication adherence. Such initiatives have been strengthened owing to the availability of connected devices and other digital solutions, which allow patients/healthcare providers to closely monitor and improve drug adherence.*Example Highlights:*

    1. Currently, over 60 smart drug delivery devices are either commercially available or are under development for improving adherence to medication. More than 50% of these devices are smart inhalers or smart injectors. Examples of smart inhalers and smart injectors include (in alphabetical order, no selection criteria) 3M Intelligent Control Inhaler (3M), BETACONNECT (Medicom Innovation Partner), eMDI (H&T Presspart), Flexi-Q eMU-P and Flexi-Q eMU-C (Elcam Drug Delivery Device), GoCap (Common Sensing), Propeller (Propeller Health), SMARTTURBO, SMARTTOUCH and SMARTTOUCH AV (Adherium), and SmartPilot and YpsoMate Smart (Ypsomed).
    2. In addition, there are close to 75 smart accessory devices that are either commercially available or are under development. Of these, over 40% are smart medication dispensers. Noteworthy examples of such products include (in alphabetical order, no selection criteria) Evondos E300 (Evondos), HERO (HERO Health), Maya and Jon (MedMinder Systems), MedaCube (PharmaAdva) and Philips Medido (Philips), Pillo (Pillo Health) and SIMPLEMED+ (Vaica).
    3. Around 70% of the companies that are involved in the development of smart drug delivery systems and smart accessory systems are small-sized players/start-ups (having less than 50 employees). Examples of such companies include (in alphabetical order, no selection criteria) Aerobit Health, Airbrio, Arthur Health, Cognita Labs, CuePath Innovation, DayaMed, etectRx, MedMinder Systems, PharmRight, Popit, Portal Instruments, and Wealth Taxi.
    4. Over 50 compliance packaging systems are available to promote medication adherence among patients suffering from chronic clinical conditions; these include blister packs, pouches and dose cups. Companies engaged in the development of such products include (in alphabetical order, no selection criteria) Dispill-USA (Dispill Multi-dose Packaging), Keystone Folding Box (Ecoslide-RX, Key-Pak and Key-Pak Plus), Omnicell (Opti-Pak and SureMed), Parata Systems (Parata PASS Pack) and TCGRx (AdherePac and AdhereCard)
    5. Many standalone mobile applications are also available for improving compliance to prescribed therapeutic regimens. As of July 2018, over 200 such mobile applications, having user ratings of more than four, were available on Google Play Store. It is worth mentioning that more than 70% smart drug delivery and accessory devices that we came across have a supporting mobile application.
    6. Close to 180 partnerships have been inked between various stakeholders within the industry over the last few years; of these, over 100 collaborations were signed since 2016. Most of the deals that we came across were product development agreements (53%), signed between players to include new features in their products or advance their development programs. Examples of recently established deals include collaborations between Ypsomed and JDRF (August 2018), Adherium and Vitalus Health (August 2018), Amiko Digital Health and Luz Sade (July 2018), Becton Dickinson and Helmer Scientific (June 2018), Common Sensing and Flex (May 2018), and Compliance Meds Technologies and Oracle Health Sciences (April 2018),
    7. Since 2001, nearly USD 2.5 billion has been invested in companies operating in the field of medication adherence. Interestingly, close to half of the total amount (USD 1.1 billion) was raised between 2015 and August 2018, indicating the rising interest of strategic investors in this domain. Examples of players that have managed to secure capital investments in multiple rounds include Proteus Digital Health, NantHealth, Tandem Diabetes Care, Propeller Health and Cellnovo.
    8. The drug adherence market is expected to grow at an annualized rate of more than 15.4% between 2018 and 2030. It is important to highlight that North America (primarily the US) and Europe currently capture the largest share of the overall market. This is followed by Asia-Pacific and the rest of the world. As the industry matures, we expect the market in Asia-Pacific to grow owing to the sizable user base in the region.

    *Key Topics Covered*
    1. Preface

    1.1. Scope of the Report
    1.1. Research Methodology
    1.2. Chapter Outlines

    2. Executive Summary

    3. Introduction
    3.1. Medication Non-Adherence: A National Epidemic
    3.2. Medication Adherence and its Measurement
    3.3. Types of Medication Non-Adherence
    3.4. Improving Medication Adherence
    3.5. Key Initiatives to Improve Medication Adherence

    4. Smart Drug Delivery Devices: Current Market Landscape
    4.1. Chapter Overview
    4.2. Smart Drug Delivery Devices: Overall Market Landscape

    5. Smart Accessory Devices And Packaging Systems: Current Market Landscape
    5.1. Chapter Overview
    5.2. Smart Accessory Devices: Overall Market Landscape
    5.3. Compliance Packaging Systems: Overall Market Landscape

    6. Regulatory Landscape For Connected Drug Delivery Systems
    6.1. Chapter Overview
    6.2. North America
    6.3. Europe
    6.4. Latin America
    6.5. Asia-Pacific
    6.6. Middle East
    6.7. Connected Devices: Demonstrating Safety, Effectiveness and Performance
    6.8. Connected Devices: Ensuring Security of Data Captured

    7. Drug Delivery Devices: Company Profiles
    7.1. Chapter Overview
    7.2. Adherium
    7.3. BIOCORP
    7.4. nGageIT Digital Health
    7.5. Proteus Digital Health
    7.6. SOOIL Development
    7.7. Ypsomed

    8. Accessory Devices: Company Profiles
    8.1. Chapter Overview
    8.2. AARDEX Group
    8.3. Information Mediary
    8.4. MedMinder Systems
    8.5. Philips
    8.6. Tinylogics
    8.7. Vaica

    9. Case Studies
    9.1. Chapter Overview
    9.2. Case Study I: Diabetes
    9.3. Case Study II: Asthma
    9.4. Case Study III: Rheumatoid Arthritis

    10. Product Competitiveness Analysis
    10.1. Chapter Overview
    10.2. Methodology
    10.3. Overall Product Competitiveness Analysis

    11. Funding and Investment Analysis
    11.1. Chapter Overview
    11.2. Types of Funding
    11.3. Drug Adherence Enhancement Market: Funding and Investment Analysis
    11.4. Concluding Remarks

    12. Partnerships and Collaborations
    12.1. Chapter Overview
    12.2. Partnership Models
    12.3. Drug Adherence Enhancement Market: List of Partnerships and Collaborations

    13. Medication Adherence With Mobile Applications
    13.1. Chapter Overview
    13.2. The Increasing Trend of Mobile Applications in Healthcare Industry
    13.3. USFDA Regulations for Mobile Medical Applications
    13.4. List of Mobile Applications for Improving Medication Adherence
    13.5. Medication Adherence with Mobile Applications: Clinical Research Evidence

    14. Market Forecast
    14.1. Chapter Overview
    14.2. Forecast Methodology and Key Assumptions
    14.3. Global Drug Adherence Enhancement Market
    14.4. Global Drug Adherence Enhancement Market: Distribution by Geography, 2018-2030 (By Value)
    14.5. Global Drug Adherence Enhancement Market: Distribution by Type of Product and Geography (By Value)
    14.6. Global Drug Adherence Enhancement Market: Distribution by Type of Product (By Volume)
    14.7. Global Drug Adherence Enhancement Market: Distribution by Therapeutic Area and Geography (By Value)
    14.8. Global Drug Adherence Enhancement Market: Distribution by Therapeutic Area and Geography (By Volume)
    14.9. Global Drug Adherence Enhancement Market: Distribution by Route of Drug Administration and Geography (By Value)
    14.10. Global Drug Adherence Enhancement Market: Distribution by Route of Drug Administration and Geography (By Volume)

    15. Conclusion
    15.1. Poor Adherence to Therapies for the Treatment of Chronic Disorders Poses a Significant Economic Burden on the Healthcare Industry
    15.2. Presently, Several Players are Developing IoT-Enabled / Connected Devices for Improving Medication Adherence; Majority of these are Small-sized Companies based in the US
    15.3. Increasing Financial Support from Various Investors is Indicative of Future Opportunities related to Novel Strategies for Medication Adherence Improvement
    15.4. Players have Entered into Strategic Collaborations to Support the Development of their Smart Products
    15.5. Availability of Standalone, as well as Companion Mobile Applications, is Expected to Provide a More Integrated Approach for Improving Adherence
    15.6. With Increasing Focus on Improving Therapy Efficacy and Alleviating Healthcare Burden, the Overall Market is Anticipated to Witness Steady Growth

    16. Executive Insights
    16.1. Chapter Overview
    16.2. AARDEX Group
    16.3. AceAge
    16.4. AdhereTech
    16.5. Amiko Digital Health
    16.6. Cognita Labs
    16.7. etectRx
    16.8. PharmAdva
    16.9. Popit Technologies
    16.10. Wealth Taxi
    16.11 Small-sized Company

    * Companies Featured*· 3M
    · 5AM Ventures
    · 7wire Ventures
    · 91streets Media Technologies
    · AARDEX Group
    · AARP
    · Abbott
    · Abiogenix
    · AceAge
    · Acintyo
    · Acta Distribution
    · ActiveCare
    · Adams Street Partners
    · AdhereTech
    · Adherium
    · Administracin Nacional de Medicamentos, Alimentosy Tecnologa Mdica
    · Advent Venture Partners
    · Aerobit Health
    · AeroSonix
    · Aguettant
    · Agncia Nacional de Vigilncia Sanitria (National Health Surveillance Agency)
    · Air Liquide Healthcare
    · AIRBRIO
    · Airnest
    · Allscripts
    · Altran
    · Amarutek
    · Amazon
    · AMC Health
    · American Academy of Allergy, Asthma and Immunology
    · American Heart Association
    · Amerigroup
    · Amgen
    · Amiko Digital Health
    · ANTARGYAN CLOUDWORKS
    · ApnaCare India
    · Apollo Diabetes Care Management
    · Apolotus Health Solution
    · Apoteket
    · App Singularity
    · AppAttic
    · Appgraid Apps
    · AppQuik
    · AppTrailz
    · Aptar Pharma
    · Area9 Innovation
    · Arthur Health
    · Artmedus
    · ARTORG Center
    · AS PHARM SOFT
    · Asheville Angels
    · Asho Soft Tech
    · Asset Management Ventures
    · Asthma and Respiratory Foundation New Zealand
    · AstraZeneca
    · AT&T
    · Aterica Digital Health
    · August Faller Group
    · Auriga Partners
    · Australasian Medical & Scientific
    · Austrian Chamber of Pharmacists
    · Automated Security Alert
    · Aventyn
    · Avery Dennison Medical Solutions
    · Avnet Integrated Solutions
    · Baviux
    · Bayer
    · Becton Dickinson
    · BERG
    · Bigfoot Biomedical
    · BioAdvance
    · BioAssist
    · BIOCORP
    · BioMark Health
    · BioScience Managers
    · BIVA
    · Blackberry
    · BlackPearls
    · Blueprint Health
    · Boehringer Ingelheim
    · Bosch
    · Brain Tech
    · Brainovations Education Excellence
    · Breed Reply
    · Butterfly Ventures
    · C Square Info Solutions
    · C-Square Info Solutions
    · C3HealthLink
    · caiocrol
    · California HealthCare Foundation
    · California Highlands Addiction Treatment
    · Cambridge Consultants
    · Cambridge Enterprise
    · Canada Innovation Acceleration Investment
    · Capital Angels
    · Capital Royalty Partners II
    · Cardinal Health
    · CareCentra
    · CareConsult
    · CareZone
    · Catalent Pharma Solutions
    · Celgene
    · Cellnovo
    · Cenduit
    · Centers for Disease Control and Prevention
    · Centers for Medicare & Medicaid Services
    · Central Drugs Standard Control Organization
    · Centric Health
    · Chalmers Ventures
    · CheckTheMeds Technology
    · Children's Hospital of Philadelphia
    · China Food and Drug Administration
    · CHORDAS
    · Chronicare
    · Cigna Health Insurance
    · Cincinnati Children's Hospital Medical Center
    · Circadian Design
    · Clifton R Farris
    · CML Advocates Network
    · Cognita Labs
    · Cognitive Healthcare
    · Cohero Health
    · Colbert Packaging
    · Comisin Federal para la Proteccin contra Riesgos Sanitarios
    · Common Sensing
    · Community Care Network of Virginia
    · Companion Medical
    · Compliance Meds Technologies
    · Confrrie Clinique
    · Connecticut Children's Medical Center
    · Core Mobile
    · Credit Agricole Private Equity
    · Crux Product Design
    · CSL Behring
    · CUCO Health
    · CuePath Innovation
    · Curatio
    · Curis
    · Cyft
    · DayaMed
    · Debiotech
    · Decision Machines
    · DeepBench
    · Delphi Ventures
    · Desert Oasis Healthcare
    · DeskShare
    · Dexcom
    · Diabeloop
    · Diasend
    · Digital Pharmacist
    · Diplomat Pharmacy
    · Disetronic Group
    · Dispill-USA
    · DistriMedic
    · DocRoSh Health
    · Domain Associates
    · Dosecast
    · DoseCue
    · DoseSmart
    · DOTh Solutions
    · Douglas Pharmaceuticals
    · Drug Package
    · Duke University
    · DYN Diagnostics
    · E Ink
    · EcoloPharm
    · Edmond de Rothschild
    · Elcam Drug Delivery Devices (E3D)
    · Eli Lilly
    · Elkstone Capital Partners
    · EMedStore Pharma IT
    · emocha Mobile Health
    · Emperra E-Health Technologies
    · Enable Injections
    · Enercon Technologies
    · EnvoyHealth
    · Essex Woodlands
    · etectRx
    · ETHIO APPS
    · Eularis
    · European Investment Bank
    · European Medicines Agency
    · Evalan
    · Everwell Health Solutions
    · Everwin Precision Technology
    · Evondos
    · Excell Partners
    · Experts in Communications and Connectivity Technology (ECCT)
    · Express Scripts
    · Fagor Healthcare
    · Fedefarma
    · Fidelity International
    · FindAir
    · Fletcher Spaght Ventures
    · Flex
    · Forbion Capital Partners
    · Frost & Sullivan
    · GalileoMD
    · Gecko Health Innovations
    · GenieMD
    · Genome BC
    · GIS Strategic Ventures
    · GlaxoSmithKline
    · Global Emerging Markets Group
    · Gloria Pharmaceuticals
    · GlucoRx
    · GoodCare Pharma
    · GoodRx
    · GoodVent Beteiligungsmanagement
    · GoSmart
    · H&T Presspart
    · H&Y Apps
    · Hackensack Meridian Health
    · HAP Innovations
    · Haselmeier
    · HCL Technologies
    · Health Bot
    · Health Canada
    · Health Care Originals
    · Health Department of Oslo
    · Health Mission
    · Health Monitor
    · Health's Angel
    · HealthBeacon
    · Healthbox
    · HealthCare Ventures
    · Healthcom
    · Healtheoz
    · Healthio
    · HealthPrize Technologies
    · Heitkamp & Thumann Group
    · Helmer Scientific
    · Hepatitis Victoria
    · HERO Health
    · Hexoskin
    · Hikma Ventures
    · Home Diagnostics
    · HP Labs
    · HTC
    · Human API
    · Humana
    · IAP Labs
    · IDEAL LIFE
    · ImageWare Systems
    · ImagineCare
    · Immunex
    · Information Mediary
    · Innospence
    · Innovation Zed
    · INRange Systems
    · Inspirit Innovations
    · Insulin Pump Hellas
    · Intelligent Devices SEZC
    · Intelligent Product Solutions
    · Intent Solutions
    · International Diabetes Federation
    · International Federation of Pharmaceutical Manufacturers and Associations
    · Intigate Technologies
    · Investitionsbank des Landes Brandenburg
    · Irody
    · IRWAA
    · iSense
    · ITmedicus
    · Itochu
    · IVAX
    · Jabil
    · Janssen Pharmaceutica
    · JDRF
    · Jiangsu Delfu Medical Device
    · Jones Packaging
    · Joslin Diabetes Center
    · Journey Health Labs
    · JVS Technologies
    · K-svets
    · Kaiser Permanente Ventures
    · KCRise Fund
    · Keystone Folding Box
    · Konkuk University
    · Korl Medical Center
    · Kreos Capital
    · Kuwait Investment Authority
    · Life Integrating Technologies and Experiences (LITE)
    · Life Sciences Angel Network
    · LifeMatters
    · LloydsPharmacy
    · Lohmann Therapie Systeme
    · lool Ventures
    · Lowcountry Angels
    · LoyAlerts
    · LSDinfotech
    · Luz Sade
    · M Ventures
    · M2M Datasmart
    · Maangata Apps
    · Maccabi Healthcare Services
    · Mail-Meds
    · Maj Invest Equity
    · Manchac Technologies
    · Mango Health
    · Manrex
    · Manyeta
    · MAP Health Management
    · Marketaro
    · MassChallenge
    · Maxerence
    · McKesson
    · MeadWestvaco
    · MedApps
    · MedControl Technologies
    · MedCrypt
    · Medexpert
    · Medical International Research
    · Medical Research Institute of New Zealand
    · Medical Specialties Australia
    · Medication Solutions
    · Medicine-On-Time
    · Medico Pak
    · Medicom Innovation Partner
    · MedicPen
    · Medimate
    · Medipense
    · Medisafe
    · MedMinder Systems
    · Medocity
    · MedPak Pharmacy
    · MedReady
    · MedSmart
    · Medtronic
    · Medtrum
    · MENA Apps
    · Merck
    · Metro Health
    · Mevia
    · MicroHealth
    · Ministry of Food and Drug Safety
    · Ministry of Health, Labour and Welfare
    · MivaTek Smart Connect
    · Molina Healthcare
    · Montuno Software
    · Mount Sinai Health System
    · Movi
    · MphRx
    · Multiframes
    · Mylan
    · MyMeds
    · MyTherapy
    · NantHealth
    · Nath IT Solutions
    · National Competent Authority
    · National Consumers League
    · National Institute of Mental Health (NIMH)
    · National Institutes of Health
    · Navia Life Care
    · NaviMed
    · NBGI Ventures
    · NECTEC
    · Nemera
    · NESTA
    · Nestl Health Science
    · New Directions Technology Consulting
    · New World Health
    · New Zealand Medical & Scientific
    · NexusLink Services
    · nGageIT Digital Medicine
    · Noble International
    · NOPII
    · Novalab Ibrica
    · Novartis
    · Novo Nordisk
    · Now Healthcare Group
    · NPS MedicineWise
    · Octopus Ventures
    · Office of the National Coordinator for Health Information Technology Omnicell
    · Omron Healthcare
    · One Drop
    · Onward Care Technologies
    · Oracle Health Sciences
    · Orbita
    · ORI Healthcare Fund
    · Otsuka Pharmaceutical
    · Oxford Finance
    · Oyster Capital Partners
    · P5 Health Ventures
    · Palladio Group
    · Parata Systems
    · Partners HealthCare
    · PatientPartner
    · PBJ Capital
    · Pear Therapeutics
    · Pegasystems
    · Peppermint VenturePartners
    · PhableCare
    · Pharmacell Medication Systems
    · Pharmaceutical and Medical Devices Agency
    · PharmAdva
    · PharmaSens
    · PharmRight
    · Philips
    · Phillips-Medisize
    · Phoenix Healthcare
    · Picomol Healthcare
    · PillDrill
    · Pillo Health
    · PillPack
    · Pitango Venture Capital
    · Play-it Health
    · PMA Pharmacy
    · Poliweb Graphics
    · Popit
    · Portal Instruments
    · Practo
    · Prescription Notification Group
    · Prescription Solutions
    · ProCare Rx
    · Propeller Health
    · Proteus Digital Health
    · PRPL
    · Qualcomm Life
    · Quantum Pharmaceutical
    · Quido Healthcare Services
    · QuiO Technologies
    · Quizora Media
    · Raffles Medical Group
    · Ramtin Software Solutions
    · Raneem Technologies
    · Recovery Centers of America
    · RemindTrac
    · Renata
    · Research Institute of the McGill University Health Centre
    · Resolve Digital Health
    · Respia
    · Rex Medical
    · Risk Cooperative
    · Robert Bosch Venture Capital
    · Roche
    · RockTenn
    · Rubin Medical
    · RxAdvance
    · RxNetworks
    · RXVIP Concierge
    · Safeguard Scientifics
    · Safeway
    · Sagentia
    · Samsung
    · Samsung NEXT
    · Sanner Group
    · Sanofi
    · Sanofi-Sunrise
    · Saudi Food and Drug Authority
    · Schreiner MediPharm
    · SCRA Technology
    · Second Technology Capital Investors
    · SentiCare
    · Seoul National University
    · Serendipity Partners
    · SHL Group
    · Silicon Valley Bank
    · Simplified APP Solutions
    · Sino Portfolio
    · Sinwho
    · SmarterHealth TechServe
    · Smartgateways
    · Smiths Medical
    · Smooth Apps Studio
    · SMRxT
    · Social Capital
    · Soft Industry Alliance
    · Sonceboz
    · SOOIL Development
    · South Carolina Angel Network
    · Spartanburg Angels
    · Spring Ridge Ventures
    · Sprint
    · Spyzar Studios
    · SR One
    · St. Helena Health
    · St. Jude Medical
    · STAAR Alert
    · Sunrise Labs
    · SuperAndroidApp
    · Swanhill Capital
    · Syqe Medical
    · Takeda Pharmaceutical
    · Tandem Diabetes Care
    · TCGRx
    · Techizer Tech Solutions
    · Tekes
    · TerraNovita
    · Teva Pharmaceutical
    · The Carlyle Group
    · The Cyto Cord Group
    · The Finnish Funding Agency for Technology and Innovation
    · The Kroger
    · Therapeutic Goods Administration
    · Three Leaf Ventures
    · Tidepool
    · Tillotts Pharma
    · TimerCap
    · Tinylogics
    · Tonghua Dongbao Pharmaceutical
    · TowerView Health
    · TPG Biotech
    · Triad HealthCare Network
    · Tricella
    · Trinnovate Ventures
    · TriVentures
    · TypeZero Technologies
    · UNICUS HealthReach
    · United Family Healthcare
    · United States Food and Drug Administration
    · UnitedHealthcare
    · University of Arkansas for Medical Sciences
    · University of Cambridge
    · University of Pittsburgh Medical Center
    · University of Toronto
    · Urtech Manufacturing
    · Vaica
    · Valtronic
    · Vectura Group
    · Verizon Investments
    · Virbac
    · Vishnu Global Services
    · Vitalus Health
    · Walgreens
    · Waterline Ventures
    · Wcre8tive App Developer
    · Wealth Taxi
    · Web Coast Apps
    · Welkin Health
    · West Pharmaceutical Services
    · WestRock
    · Whisper Arts
    · WMM
    · World Allergy Organization
    · World Health Organization
    · WorldMedic
    · Wyeth-Ayerst Pharmaceuticals
    · Xcenda
    · Xhale
    · Ximedica
    · XINK Laboratories
    · YOURmeds
    · YPSOMED
    · Zaffre Investments
    · Zibdy
    · Zipit Wireless

    For more information about this report visit https://www.researchandmarkets.com/research/pd2nk3/global_drug?w=12

    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

    CONTACT:
    CONTACT: ResearchAndMarkets.com
    Laura Wood, Senior Press Manager
    press@researchandmarkets.com
    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900
    Related Topics: Pharmaceuticals Reported by GlobeNewswire 4 hours ago.

    0 0

    Ethiopia aims to achieve universal health coverage (UHC) through primary health care (PHC). This requires a rapid increase in domestic spending on health. Building on almost two decades of effective technical assistance, the new Abt Associates-led USAID Health Financing Improvement Program will support this effort.

    ROCKVILLE, Md. (PRWEB) December 11, 2018

    Having met its Millennium Development Goals for reducing under-5 mortality ahead of schedule, Ethiopia is steadily moving toward better health outcomes. Per capita health spending has been growing consistently, and the share of domestic financing, including government spending on health, has increased. However, as the economy and public sector’s capacity grow, donor funding is gradually decreasing, and the health sector needs to prepare for it. Ethiopia aims to achieve universal health coverage (UHC) through primary health care (PHC). This requires a rapid increase in domestic spending on health. Building on almost two decades of effective technical assistance, the new Abt Associates-led USAID Health Financing Improvement Program will support this effort.

    Abt was recently awarded the USAID Health Financing Improvement Program, a 5-year, $39.6 million project, aimed at supporting the government of Ethiopia (GOE) to further strengthen and institutionalize health financing reforms and initiatives to provide accessible, high-quality PHC services for all Ethiopian citizens with reduced financial barriers. The Program consortium includes core partners Breakthrough International Consultants, Dimagi, the Institute for Healthcare Improvement, Results for Development and resource partner Harvard School of Public Health. The program builds on previous investments in health care financing reform by USAID and GOE. Abt and its partners will work with GOE to:

    -Increase domestic resource mobilization for the enhanced provision of quality PHC services;
    -Streamline the pooling of risk-sharing/insurance mechanisms for wider access to PHC services with reduced financial barriers;
    -Facilitate the strategic purchasing of health services from public and private health providers; and
    -Improve governance, management and evidence-generation for health financing reforms and health facilities.

    By the end of the Program in 2023, Ethiopia’s health sector is anticipated to have more resources available for primary health care services. The share of domestic financing of health care services will increase from 2014’s 64 percent to 70 percent. More people will have insurance coverage, including the poorest. Insurance programs will be made sustainable by connecting the public and the private sectors and promoting improved quality. GOE will employ evidence-based practices that engage the full spectrum of health-sector partners. Abt and its partners will work on purposefully and systematically building local capacity to institutionalize and transition Program responsibilities to these institutions for sustainable and continuous implementation.

    “We’re proud of the work we’ve done with the Ethiopian government to successfully test and scale up community-based health insurance through our previous work conducted under the USAID bilateral Health Sector Financing Reform and the global Health Finance and Governance projects,” said Catherine Thompson, Regional Managing Director with Abt Associates. “We’re excited to take this next step toward Universal Health Coverage with our partners in the government and private sector.”

    About Abt Associates

    Abt Associates is an engine for social impact, dedicated to moving people from vulnerability to security. Harnessing the power of data and our experts’ insights, we provide research, consulting and technical services globally in the areas of health, environmental and social policy, technology and international development. http://www.abtassociates.com Reported by PRWeb 4 hours ago.

    0 0

    Republica Havas selected among PR News’ 2018 Top Places to Work in the industry. PR News editors, together with an outside panel of industry experts, select winners based on the following criteria: opportunities for career development and growth, open communication, unique benefits, compensation, and diversity in the workplace, among others.

    NEW YORK (PRWEB) December 11, 2018

    Republica Havas, one of America’s leading and fastest-growing multicultural creative, media, and communications agencies, was named one of PR News’ 2018 Top Places to Work in the industry. The award was presented at a dinner at the Edison Ballroom in New York, and this year marks the second time the agency receives this recognition.

    PR News receives hundreds of entries from across all the United States, including agencies and Fortune 500 companies. PR News editors, together with an outside panel of industry experts, select winners based on the following criteria: opportunities for career development and growth, open communication, unique benefits, compensation, and diversity in the workplace, among others.

    "Our people are the heart and soul of Republica Havas. We are fiercely committed to providing a familial, collaborative culture where employees feel appreciated and inspired to do their best work as they grow professionally,” said Jorge A. Plasencia, Republica Havas co-founder, chairman and CEO. “Being named a Top Place to Work once again by PR News is definitely a feather in our cap,” added Plasencia.

    As part of its familial culture, Republica Havas offers employees many unique and exciting benefits, including a Barista brewing the agency’s famous cafecito; Breakfast Fridays; a Fitness Center; various games including Pool, Foosball, and Ping Pong; Pet Insurance; Domestic Partner Health Insurance; Birthday Holiday; Summer Fridays; Annual Offsite Retreats; Quarterly Town Hall Meetings; Field Trips; and regular raffles to the best sports, concerts and community events. Additionally, the agency offers regular yoga and meditation practices on its rooftop terrace.

    For a full list of winners, click here.

    About Republica Havas

    Republica Havas is one of America’s leading and fastest-growing multicultural creative, media, and communications agencies. Through its “Rethink Relevant” strategic mantra, Republica Havas provides integrated services including strategy, creative, research, media planning and buying, analytics and consumer science, digital, public relations, social, and experiential to numerous blue-chip clients in the U.S. and markets around the world. Founded in 2006 and based in Miami, Florida, Republica Havas is part of Havas Group, a division of Paris-based Vivendi. For more information, visit republicahavas.com, and follow @RepublicaHavas and #RethinkRelevant on social media. Reported by PRWeb 1 day ago.

    0 0

    The National Health Insurance Scheme (NHIS) has achieved only about three percent coverage since 2005

    The post Group urges Nigerian govt. to ensure 60 percent health insurance coverage by 2024 appeared first on Premium Times Nigeria. Reported by Premium Times Nigeria 7 hours ago.

    0 0

    Reported by SeekingAlpha 6 hours ago.

    0 0

    Dublin, Dec. 12, 2018 (GLOBE NEWSWIRE) -- The "World Market for Precision Cancer Diagnostic Tests" report has been added to *ResearchAndMarkets.com's* offering.*World Market for Precision Cancer Diagnostic Tests*, a market-based and industry-focused report, examines the global market environment for precision cancer testing products and procedures, including the following data:

    · Market for Precision Cancer Testing, IVD and Imaging, 2018-2023
    · Global Precision Cancer Diagnostic Testing Product Demand by Type & Geographical Market, 2018-2023

    · Precision Cancer Diagnostic Testing Procedural Volume by Type, 2018-2023
    · Global Precision Cancer Diagnostic Testing Procedures by Type, 2018-2023*Procedures & Products*

    The volume of precision cancer-related procedures is projected to rise. Several trends and factors will influence growth. Advances in imaging and molecular technologies will lead to the introduction of new tests with enhanced tumor specificity and sensitivity.

    The upgrading and modernization of medical delivery systems in many countries will make more funding available for cancer care. An increasing emphasis on preventive medicine in global healthcare will boost demand for tests that enable the early detection of tumors.

    *The report provides the following market data points:*

    · Global Precision Cancer Diagnostic Procedural Volume, 2018-2023
    · Global Precision Cancer Diagnostic Product Demand, 2018-2023
    · Global Cancer Imaging Procedural Volume, 2018-2023
    · Global Cancer Imaging Product Demand, 2018-2023

    · Global Molecular Cancer Testing Procedural Volume, 2018-2023

    · Global Molecular Cancer Testing Product Demand, 2018-202
    · Global In Situ Hybridization (ISH) Cancer Testing Procedural Volume & Product Demand, 2018-2023
    · Global Blood-Based Molecular Cancer Testing Procedural Volume & Product Demand, 2018-2023
    · Global HPV Genotyping Cancer Testing Procedural Volume & Product Demand, 2018-2023
    · Global Next-Generation Sequencing (NGS) Cancer Testing Procedural Volume & Product Demand, 2018-2023
    · Global Mass Spectrometry (MS) Cancer Testing Procedural Volume & Product Demand, 2018-2023
    · Selected Mass Spectrometry-Based Oncology Tests
    · Global Circulating Tumor Cell Cancer Testing Procedural Volume & Product Demand, 2018-2023
    · Global Pharmacodiagnostic (PCD) Cancer Testing Procedural Volume & Product Demand, 2018-2023
    · Global Microarray Cancer Testing Procedural Volume & Product Demand, 2018-2023
    · Global Histology/Cytology Cancer Testing Procedural Volume, 2018-2023

    · Global Histology/Cytology Cancer Testing Product Demand, 2018-2023
    · Global Pap Test Procedural Volume & Product Demand, 2018-2023
    · Global Immunohistochemistry (IHC) Cancer Testing Procedural Volume & Product Demand, 2018-2023
    · Global Flow Cytometry Cancer Testing Procedural Volume & Product Demand, 2018-2023
    · Global Other Histology/Cytology (H/C) Cancer Testing Procedural Volume & Product Demand, 2018-2023
    · Global Tumor Marker Immunoassay Procedural Volume & Product Demand, 2018-2023
    · Global Tumor Marker Immunoassay Product Demand by Type, 2018-2023
    · Global POC Colon Cancer Testing Procedural Volume & Product Demand, 2018-2023

    *Geographic Markets*

    The size and growth potential of geographical markets for precision cancer diagnostic procedures and products vary widely from country to country due to differences in demographic patterns, lifestyles trends, health insurance coverage, healthcare spending intensity, medical delivery systems, patient care approaches, and price controls.

    Based on a high level of national health expenditures and patient activity, the US market will remain the largest and most diversified. The report surveys precision cancer testing indicators for 2018 to 2023, including new cancer cases (thousand), precision cancer diagnostic procedures (million), and precision cancer diagnostic product demand (mil US$), across the following geographic markets:

    · United States
    · Canada
    · Mexico
    · Western Europe
    · France
    · Germany
    · Italy
    · Spain
    · United Kingdom
    · Other Western Europe
    · Asia/Pacific
    · Australia
    · China
    · India
    · Japan
    · Other Asia/Pacific
    · Brazil
    · Other Central & South America
    · Eastern Europe
    · Africa/Middle east

    *Industry Structure*

    The global precision cancer diagnostics segment includes approximately 300 participants, ranging in size from small, narrowly focused firms to large, diversified multinational companies. Since precision cancer diagnostics serve health care applications, they are subject to strict government regulations and serve highly price-sensitive markets.

    Overall success in the industry requires an effective balancing of research and development productivity, manufacturing efficiencies, effective marketing and distribution, and responsive customer service.

    *World Market for Precision Cancer Diagnostic Tests* explores the activities of selected companies involved in the segment to serve as a representative sample of competitors active in the business.

    *The companies profiled in the report include the following:*

    · Abbott Laboratories
    · Agilent Technologies, Inc.
    · Angle plc
    · Becton Dickinson and Company
    · Bio-Rad Laboratories, Inc.
    · Biocartis N.V.
    · Biocept, Inc.
    · bioMerieux SA
    · Canon Medical Systems Corporation
    · Cynvenio Biosystems, Inc.
    · Danaher Corporation
    · Epigenomics AG
    · Exact Sciences Corporation
    · Exosome Diagnostics, Inc.
    · Foundation Medicine, Inc.
    · General Electric Company
    · Genomic Health, Inc.
    · Hologic, Inc.
    · Illumina, Inc.
    · Menarini Silicon Biosystems SpA
    · Myriad Genetics, Inc.
    · NanoString Technologies, Inc.
    · Ortho Clinical Diagnostics
    · QIAGEN N.V.
    · Randox Laboratories Ltd.
    · Roche Holding AG
    · Royal Philips N.V.
    · Siemens AG
    · Thermo Fisher Scientific
    · Vela Diagnostics

    Included in the demand estimates and forecasts that appear in this report are the value of reagents and other consumables employed directly in precision cancer procedures and a percentage of the value of instruments and systems purchased by end users.

    This percentage reflects the portion of total IVD and imaging tests that involve cancer-related applications. The analysis covers commercially sold and distributed tests only. Laboratory-developed tests (LDTs) and tests used for research purposes are excluded from the discussion.

    *Key Topics Covered*

    1. Executive Summary

    · Introduction
    · Scope & Methodology
    · IVD and Imaging Markets
    · Product Overview
    · Procedure Volume
    · Procedural Product Costs

    2. Market Environment

    · Overview
    · Macroeconomic Environment
    · Gross Domestic Product
    · Per Capita Gross Domestic Product
    · Demographic Trends
    · Population
    · Age Distribution
    · Global Healthcare Trends
    · National Health Expenditures
    · Hospitals
    · Physicians
    · Patient Activity

    3. Cancer Statistics

    · Overview
    · Regional/National Trends
    · New Cancer Cases by Site
    · Lung Cancer
    · Breast Cancer
    · Colorectal Cancer
    · Prostate Cancer
    · Stomach Cancer
    · Liver Cancer
    · Esophageal Cancer
    · Cervical Cancer
    · Thyroid Cancer
    · Bladder Cancer
    · Non-Hodgkin Lymphoma
    · Pancreatic Cancer
    · Leukemia
    · Kidney Cancer
    · Uterine Cancer
    · Lip & Oral Cavity Cancer
    · Pharynx Cancer
    · Brain/Central Nervous System Cancer
    · Ovarian Cancer
    · Skin Melanoma
    · Gallbladder Cancer
    · Larynx Cancer
    · Multiple Myeloma
    · Other Cancers

    4. Procedures & Products

    · Overview
    · Cancer Imaging
    · Types of Tests
    · Applications
    · Ultrasound
    · Computed Tomography
    · Magnetic Resonance Imaging
    · Digital Mammography
    · Positron Emission Tomography
    · Analog Mammography
    · Digital Breast Tomosynthesis
    · Molecular Breast Imaging
    · Other Cancer Imaging
    · Molecular Cancer Testing
    · In Situ Hybridization
    · Blood-Based Molecular Cancer Tests
    · HPV Genotyping
    · Next-Generation Sequencing Tests
    · Mass Spectrometry (MS) Tests
    · Circulating Tumor Cell (CTC) Tests
    · Pharmacodiagnostic Tests
    · Microarray Tests
    · Histology/Cytology Cancer Tests
    · Pap Tests
    · Immunohistochemistry Tests
    · Flow Cytometry Tests
    · Other Histology/Cytology Cancer Tests
    · Tumor Marker Immunoassays
    · Overview
    · Tumor Markers by Type
    · Companies
    · Point of Care Colorectal Cancer Tests
    · Ethical Tests
    · Over-the-Counter Tests

    5. Geographic Markets

    · Overview
    · United States
    · Healthcare Environment
    · New Medicare CLFS
    · Value-Based Healthcare Plans
    · Patient Protection and Affordable Care Act
    · Personalized Medicine & Next-Generation Sequencing
    · Laboratory Developed Tests (LDTs)
    · Healthcare Trends
    · Canada
    · Mexico
    · Western Europe
    · France
    · Germany
    · Italy
    · Spain
    · United Kingdom
    · Other Western Europe
    · Asia/Pacific
    · Australia
    · China
    · India
    · Japan
    · Other Asia/Pacific
    · Brazil
    · Other Central & South America
    · Eastern Europe
    · Africa/Mideast

    6. Industry Structure

    · Company Profiles
    · Abbott Laboratories (Abbott Park, Illinois, United States)
    · Agilent Technologies, Inc. (Santa Clara, California, United States)
    · Angle plc (Guildford, Surry, United Kingdom)
    · Becton Dickinson and Company (Franklin Lakes, New Jersey, United States)
    · Bio-Rad Laboratories, Inc. (Hercules, California, United States)
    · Biocartis N.V. (Mechelen, Belgium)
    · Biocept, Inc. (San Diego, California, United States)
    · bioMerieux SA (Marcy l'Etoile France)
    · Canon Medical Systems Corporation (Tochigi, Japan)
    · Cynvenio Biosystems, Inc. (Westlake Village, California, United States)
    · Danaher Corporation (Washington, D.C., United States)
    · Epigenomics AG (Berlin, Germany)
    · Exact Sciences Corporation (Madison, Wisconsin, United States)
    · Exosome Diagnostics, Inc. (Waltham, Massachusetts, United States)
    · Foundation Medicine, Inc. (Cambridge, Massachusetts, United States)
    · General Electric Company (Boston, Massachusetts, United States)
    · Genomic Health, Inc. (Redwood City, California, United States)
    · Hologic, Inc. (Marlborough, Massachusetts, United States)
    · Illumina, Inc. (San Diego, California, United States)
    · Menarini Silicon Biosystems SpA (Castel Maggiore, Bologna, Italy)
    · Myriad Genetics, Inc. (Salt Lake City, Utah, United States)
    · NanoString Technologies, Inc. (Seattle, Washington, United States)
    · Ortho Clinical Diagnostics (Raritan, New Jersey, United States)
    · QIAGEN N.V. (Venlo, The Netherlands)
    · Randox Laboratories Ltd. (Crumlin, County Antrim, United Kingdom)
    · Roche Holding AG (Basel, Switzerland)
    · Royal Philips N.V. (Amsterdam, The Netherlands)
    · Medical Imaging
    · Digital Pathology
    · Siemens AG (Munich, Germany)
    · Thermo Fisher Scientific (Waltham, Massachusetts, United States)
    · Vela Diagnostics (Singapore)

    For more information about this report visit https://www.researchandmarkets.com/research/5jb7vp/world_market_for?w=12

    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

    CONTACT:
    CONTACT: ResearchAndMarkets.com
    Laura Wood, Senior Press Manager
    press@researchandmarkets.com
    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900
    Related Topics: Diagnostics Reported by GlobeNewswire 5 hours ago.

    0 0

    Dublin, Dec. 12, 2018 (GLOBE NEWSWIRE) -- The "Global Wilson's Disease Drugs Market 2019-2023" report has been added to *ResearchAndMarkets.com's* offering.

    The increase in strategic alliances to help market grow. Pharmaceutical companies are engaging in strategic alliances for the development of medications for the treatment of Wilson's disease. These alliances enhance the R&D activities for new drugs for the treatment of Wilson's disease. The analysts have predicted that the Wilson's disease drugs market will register a CAGR of almost 6% by 2023.

    *Market Overview*

    Increasing introduction of patient assistance programs

    Patient assistance programs have been introduced to help patients who lack health insurance or prescription drug coverage to obtain the medications they need.

    *High cost of treatment*

    Despite the benefits of chelators, the price of these medicines poses a challenge to the market growth. The high cost of chelators will result in low patient adherence to chelator therapy. This, in turn, will hinder the growth of the global Wilson's disease drugs market.

    For the detailed list of factors that will drive and challenge the growth of the Wilson's disease drugs market during the 2019-2023, view this report.

    *Competitive Landscape*

    The market appears to be fragmented and with the presence of several companies including Bausch Health Companies and Mylan the competitive environment is quite intense. Factors such as the rising increase in strategic alliances and increasing introduction of patient assistance programs, will provide considerable growth opportunities to Wilson's disease drugs manufactures. Bausch Health Companies, Mylan, Teva Pharmaceutical Industries, TSUMURA and Recordati are some of the major companies covered in this report.

    With the presence of a considerable number of companies, this market appears to be fragmented. The strategic alliances enhance the R&D activities for new drugs for the treatment of Wilson's disease. Such alliances help companies develop new drugs for the treatment of Wilson's disease. It also helps in the faster development of therapeutic products.'

    *Key Topics Covered:*

    *PART 01: EXECUTIVE SUMMARY*

    *PART 02: SCOPE OF THE REPORT*

    *PART 03: MARKET LANDSCAPE*

    · Market ecosystem
    · Market characteristics
    · Market segmentation analysis

    *PART 04: MARKET SIZING*

    · Market definition
    · Market sizing 2018
    · Market size and forecast 2018-2023

    *PART 05: FIVE FORCES ANALYSIS*

    · Bargaining power of buyers
    · Bargaining power of suppliers
    · Threat of new entrants
    · Threat of substitutes
    · Threat of rivalry
    · Market condition

    *PART 06: MARKET SEGMENTATION BY PRODUCT*

    · Market segmentation by product
    · Comparison by product
    · Chelators - Market size and forecast 2018-2023
    · Minerals - Market size and forecast 2018-2023
    · Market opportunity by product

    *PART 07: CUSTOMER LANDSCAPE*

    *PART 08: GEOGRAPHIC LANDSCAPE*

    · Geographic segmentation
    · Geographic comparison
    · Americas - Market size and forecast 2018-2023
    · EMEA - Market size and forecast 2018-2023
    · APAC - Market size and forecast 2018-2023
    · Key leading countries
    · Market opportunity

    *PART 09: DECISION FRAMEWORK*

    *PART 10: DRIVERS AND CHALLENGES*

    · Market drivers
    · Market challenges

    *PART 11: MARKET TRENDS*

    *PART 12: VENDOR LANDSCAPE*

    · Overview
    · Landscape disruption
    · Competitive scenario

    *PART 13: VENDOR ANALYSIS*

    · Vendors covered
    · Vendor classification
    · Market positioning of vendors
    · Bausch Health Companies
    · Mylan
    · Recordati
    · Teva Pharmaceutical Industries
    · TSUMURA

    *PART 14: APPENDIX*

    For more information about this report visit https://www.researchandmarkets.com/research/8x2dqr/global_wilsons?w=12

    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

    CONTACT:
    CONTACT: ResearchAndMarkets.com
    Laura Wood, Senior Press Manager
    press@researchandmarkets.com
    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900
    Related Topics: Central Nervous System Drugs Reported by GlobeNewswire 4 hours ago.

    0 0

    WASHINGTON (AP) — Government numbers show health insurance sign-ups for the Affordable Care Act are down with just a few days left to enroll. That's happening even though premiums are stable, consumers have more choice and millions of uninsured people can still get financial help. The sign-up deadline is this Saturday in most states, for coverage beginning Jan. 1. Barring a sign-up surge, the nation's uninsured rate could edge up after a yearslong coverage expansion that has seen about 20 million people get health insurance. A report Wednesday from the Centers for Medicare and Medicaid Services shows nearly 20 percent fewer new customers signed up than at about the same time last year. New customers drive the growth of HealthCare. Reported by SeattlePI.com 4 hours ago.

    0 0

    SEATTLE, Dec. 12, 2018 (GLOBE NEWSWIRE) -- While human health insurance models – each with its own set of problems – are debated all over the world, medical insurance for pets is currently avoiding such criticism and can continue to do so with input from veterinarians.Human medical insurance companies often manage care and negotiate pricing, which dictates treatment options and the choice of doctors for patients. While pet insurance in North America originated in the 80s, the products offered were low-quality and included fee schedules, exclusions on hereditary and congenital conditions, and penalties when pets were “unlucky” and needed to use the insurance.

    Veterinarians overwhelmingly saw the inherent flaws in these products and avoided recommending them to their clients. With veterinarians in control, and through their trustworthy influence, these substandard products ultimately failed to thrive.

    Today, there are better options.  Trupanion (Nasdaq: TRUP), a leader in medical insurance for pets throughout the U.S. and Canada, provides high-quality coverage designed specifically to enhance the relationship between a loving, responsible pet owner and their trusted family veterinarian.

    It’s important to distinguish between low-quality pet insurance of the past and high-quality medical insurance for pets available today.

    For pets covered by a Trupanion policy, the fixed percentage from the actual eligible invoice is paid regardless of what the veterinarian charges. Through Trupanion’s patented software, payout is at the time of service and paid directly into a hospital’s bank account. A Trupanion policy has no annual or lifetime payout limits or fee schedules, and pet owners can choose any veterinarian in the U.S. and Canada.

    The Trupanion policy is designed to specifically not interfere with a pets’ treatment or the recommended course of veterinary care.  For pets covered with a Trupanion policy, the member can choose any veterinarian in North America and there are no payout limits or fee schedules. The policy is for the life of the pet, so while rates will reflect the cost of veterinary care, coverage remains consistent for its members.

    Dr. Steve Weinrauch, BVMS, MRCVS and chief product officer for Trupanion believes this paradigm shift will continue, with experienced veterinarians and veterinary professionals guiding the product development both internally and on the front lines in practice.

    “Veterinary input is a big part of the solution,” said Weinrauch. “We are working with thousands and thousands of practices to put our proprietary software into their hospitals and have a direct feedback loop with them. We want to hear everybody’s voice to solve today’s problems while avoiding tomorrow’s missteps.”

    As an experienced veterinarian, Weinrauch, who has practiced in hospitals in the U.S. and the U.K., understands why some colleagues fear pet medical insurance companies will attempt to manage care and negotiate fees. Veterinarians don’t want to be told how to practice medicine or what to charge for their services. And pet owners do not want to be forced into insurance-approved “in-network” veterinary hospitals. But, rather than avoiding medical insurance for pets all together, which would decrease access to care, Dr. Weinrauch urges veterinary professionals to get involved so that they are informed and have a voice.

    “Veterinarians know medicine. Trupanion is there to help responsible, loving pet owners budget for the unexpected. In doing so we enable veterinary professionals to do what they are uniquely trained and qualified to do,” said Weinrauch.

    Terms and conditions apply. Please see the full policy for details.

    *About Trupanion*
    Trupanion is a leader in medical insurance for cats and dogs throughout the United States and Canada. For almost two decades, Trupanion has helped provide pet owners peace of mind so they can focus on their pet’s recovery, not financial stress. Trupanion is committed to providing pet owners with the highest value in pet medical insurance. Trupanion is listed on NASDAQ under the symbol “TRUP.” The company was founded in 2000 and is headquartered in Seattle, Washington. In the United States, Trupanion policies are issued by its wholly owned entity, American Pet Insurance Company. In Canada, Trupanion policies are issued by Omega General Insurance Company. For more information, visit trupanion.com.

    CONTACT
    mediarelations@trupanion.com
    206-607-1930 Reported by GlobeNewswire 3 hours ago.

    0 0

    $3 million subscription contract with potential for expansion

    SAN RAMON, Calif., Dec. 13, 2018 (GLOBE NEWSWIRE) -- WANdisco (LSE: WAND), the LiveData company, is pleased to announce it has secured its largest ever cloud contract with a major US health insurer (the "Client"). The agreement is valued at approximately $3 million and will see the Client deploy the Company's patented Big Data and Cloud product, WANdisco Fusion ("Fusion").The contract is for an initial three-year subscription period valued at $3 million. The Client will start utilising Fusion for on-premise and hybrid cloud use cases. This contract leverages WANdisco’s strategic co-sell relationship with Microsoft as the Client looks to move data to the Azure cloud. The Client, one of the largest health insurers in the US, has substantial data requirements across their 22,000 employees and 15 million members representing a significant opportunity to grow the subscription over time.

    Both hybrid-cloud and cloud migration are LiveData use cases where, in order to take advantage of the significant benefits of cloud, customers must be able to move data without interruption to business operations.

    WANdisco Fusion is the only solution that can enable organisations to seamlessly move large volumes of data with consistent and continuous availability whilst meeting regulatory requirements. WANdisco's patented technology ensures our customers are able to leverage the impact of their IT investment to support exponential data growth without growing the IT budget.

    *David Richards, Chief Executive Officer and Chairman of WANdisco, commented:*

    “I am delighted to announce our largest ever cloud deal. This reflects our continued focus upon predictable recurring revenues. The $3 million contract initially spans three years, but there is significant potential to expand this further to meet their developing data requirements This contract illustrates the significant traction we are gaining in healthcare and other key industries. Our pipeline continues to grow, and we remain confident and excited about our future.”

    “The customer has vast data streams which need to be consistently and continuously available during migration to cloud, hybrid cloud and multi-cloud. WANdisco Fusion remains the only technology capable of fulfilling this. This is an excellent demonstration of how we continue to enable the migration of critical live data at scale for Microsoft Azure, and other cloud leaders.”

    This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR"). Upon the publication of this announcement, this inside information is now considered to be in the public domain.

    For the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2016/1055, this announcement is being made on behalf of the Company by David Richards, CEO and Chairman.

    *For further information please contact:*

    *WANdisco plc*
    David Richards, Chief Executive Officer and Chairman
    Erik Miller, Chief Financial Officer *via FTI Consulting*
    * * * *
    *FTI Consulting*
    Matt Dixon / Harry Staight / Chris Birt / Kwaku Aning *+44 (0)20 3727 1137*
      * *
    *Stifel (Nomad and Joint Broker)*
    Fred Walsh / Neil Shah / Alex Price / Rajpal Padam *+44 (0)20 7710 7600*
      * *
    *Peel Hunt (Joint Broker)*
    Edward Knight / Nick Prowting *+44 (0)20 7418 8900*
      * *
    *WH Ireland Limited (Joint Broker)*
    Adam Pollock *+44 (0)20 7220 1666*

    *About WANdisco*

    WANdisco is shaping the future of data infrastructure with its groundbreaking Live Data platform, enabling companies to put all their data to work for the business - all the time, at any scale.

    WANdisco makes data always available, always accurate, and always protected, delivering hyperscale economics to support exponential data growth with the same IT budget. With significant OEM relationships with IBM and Dell EMC and go-to-market partnerships with Amazon Web Services, Cisco, Microsoft Azure, Google Cloud, Hewlett Packard Enterprise, Oracle and other industry titans - as well as hundreds of customers among the Global 2000 - WANdisco is igniting a Live Data movement worldwide. Reported by GlobeNewswire 12 hours ago.

    0 0

    DFV: Amazon Alexa now with monthly payments and liability insurance *FRANKFURT AM MAIN / ACCESSWIRE / December 13, 2018 / *The Insurtech DFV Deutsche Familienversicherung AG continues its vision of insurance sales via Amazon Echo and introduces monthly payments. In addition, the insurance portfolio, which is offered through Alexa, as announced in October, also expands.

    Dr. Stefan M. Knoll, CEO of DFV: "Thanks to our flexible, event- and java-basedIT we are able to sell insurance via Amazon Echo. The use of AmazonPay as a payment method is another sign of the company's digital capability. The next step is to offer more and more of our products during Amazon Echo."

    Since this december , the Frankfurt based Insurtech also offers, as first insurance company worldwide, liability insurance via Alexa. So customers can handle the complete conclusion of a liability insurance on Amazon Echo from the advice to the payment.

    *About DFV Deutsche Familienversicherung AG (German Family Insurance)*

    DFV Deutsche Familienversicherung AG (ISIN DE000A0KPM74) was founded in 2007 as an insurance start-up with the aim of offering insurance products that people really need and understand immediately ("simple, sensible"). The Insurtech is known for its award-winning supplementary health insurance (dental, health and nursing care insurance as well as accident and property insurance). With all-digital product design and digital voice assistant connectivity, the company is setting new standards in the insurance industry.

    Further information at: www.deutsche-familienversicherung.de

    Contact:
    Lutz Kiesewetter
    Head of Corporate Communications & Investor Relations
    Telefon: 0049 69 74 30 46 396
    Telefax: 0049 69 74 30 46 46

    E-Mail: lutz.kiesewetter@deutsche-familienversicherung.de

    *SOURCE:* DFV Deutsche Familienversicherung
    View source version on accesswire.com:
    https://www.accesswire.com/530470/DFV-Amazon-Alexa-now-with-monthly-payments-and-liability-insurance Reported by Accesswire 11 hours ago.

    0 0

    TransUnion Healthcare findings reveal that hospitals may be leaving millions on the table when their revenue cycle isn’t optimized

    CHICAGO, Dec. 13, 2018 (GLOBE NEWSWIRE) -- A TransUnion Healthcare (NYSE: TRU) analysis found that 30% of self-pay accounts – those patients without health insurance or those that have a patient balance after insurance – will generate more than 80% of the self pay revenue collected by hospitals. TransUnion released this information as part of a campaign to highlight the importance of healthcare insurance discovery.The findings are significant because the number of patients without health insurance increased to more than 12% at the end of 2017. Furthermore, Patient Balances after Insurance (PBAI) have been steadily rising – increasing from 8% of the total bill responsibility in Q1 2012 to 12.2% in Q1 2017.

    Following years of decline since the Affordable Care Act was passed in 2010,^1 the uninsured rate grew from 10.9% in Q4 2016 to 12.2% in Q4 2017. As a result, hospitals are taking a much closer look at cost control measures; however, they still may be missing the most important part of the picture: an optimized revenue cycle which ensures earned revenue becomes paid revenue.

    This presents a clear opportunity for hospitals to obtain revenue from accounts that are most likely to be paid in full. More opportunities may exist on such accounts as between one and five percent of self-pay accounts that are written off as bad debt actually have billable insurance coverage.

    “Re-evaluating a hospital’s current approach can be a challenge for revenue cycle leaders, but it can result in a great reward by maximizing the healthcare providers’ overall return,” said Dave Wojczynski, president of TransUnion Healthcare. “Determining which patients or accounts may present the best opportunities for payment is just one way a healthcare provider can increase their chances of maximizing reimbursements for services rendered.”

    While some hospitals are improving their profitability via cost cutting, new research also shows that optimizing revenue cycle procedures may be of even greater benefit. In 2018, cutting costs was the highest priority for 63% of hospital C-suite executives, according to a Premier survey. Yet, a recent Advisory Board study indicated that the typical 350-bed hospital may be leaving $22 million on the table by focusing on cutting costs over optimizing their revenue cycle.^2

    “It’s important for hospitals to have systems in place that can holistically address both profitability and revenue leakage,” added Wojcyznski.

    TransUnion Healthcare’s Revenue Protection^SM solutions, including its Insurance Discovery solution, help hospitals prevent revenue leakage by engaging patients early, helping to ensure earned revenue gets paid and by optimizing their collection strategies. The company works with more than 1,800 hospitals and health systems and has protected over $4.4 billion in net revenue to date for its entire client base.

    For additional information about TransUnion Healthcare or Insurance Discovery, please click here.

    *About TransUnion Healthcare*
    TransUnion Healthcare, a wholly owned subsidiary of credit and information management company TransUnion, is a trusted provider of Revenue Protection^SM solutions that help providers collect more cash up front and throughout the revenue cycle, and identify and maximize reimbursement opportunities to reduce bad debt. By leveraging our data assets, market-leading revenue cycle management technologies, and deep insights into consumer financial behavior, our customers are better enabled to reduce uncompensated care, engage patients early and improve cash flow. www.transunionhealthcare.com

    *About TransUnion (NYSE: TRU)
    *Information is a powerful thing. At TransUnion, we realize that. We are dedicated to finding innovative ways information can be used to help individuals make better and smarter decisions. We help uncover unique stories, trends and insights behind each data point, using historical information as well as alternative data sources. This allows a variety of markets and businesses to better manage risk and consumers to better manage their credit, personal information and identity. Today, TransUnion has a global presence in more than 30 countries and a leading presence in several international markets across North America, Africa, Latin America and Asia. Through the power of information, TransUnion is working to build stronger economies and families and safer communities worldwide.

    We call this Information for Good^SM.

    http://www.transunion.com/business

    *Contact

    *       Dave Blumberg
    TransUnion

    *E-mail
    *   david.blumberg@transunion.com

    *Telephone*   312-972-6646

    ^1 https://www.cbsnews.com/news/more-americans-are-going-without-health-insurance/

    ^2 https://www.advisory.com/research/financial-leadership-council/at-the-margins/2017/06/22-million-opportunity Reported by GlobeNewswire 10 hours ago.

    0 0

    Dublin, Dec. 13, 2018 (GLOBE NEWSWIRE) -- The "Pediatric Vaccine Market, Global Forecast Infants Vaccinated, Vaccines Administered, Immunization, By Disease (Influenza, MMR, Pneumonia, Meningitis, Hepatitis, Tap, Hib, Polio, etc) & Companies" report has been added to *ResearchAndMarkets.com's* offering.Pediatric Vaccine Market is projected to exceed US$ 48 Billion by the year 2024

    Increasing government and non-government funding for the development of new vaccines, along with raising awareness about the benefits of vaccination, is certainly expected to positively drive the market growth in the coming years. In order to cut the healthcare expenses, governments have been making continuous efforts to reduce the cost of patient immunization through various vaccination programs funded by government or non-government health authorities. For example; several countries have included Children Vaccination Programs, which offers vaccines to children who lack health insurance or one who cannot afford the cost of vaccination.

    Growing prevalence of chronic diseases is another major market driver, driving the market of infant (pediatric) vaccines. The immune system is not fully developed in infants, hence they are at a higher risk of contracting severe diseases and so, vaccination plays a significant role in their prevention.According to WHO; effective immunization activities have had a major impact on reducing measles deaths. It is found that measles vaccination prevented an estimated 20.4 million deaths across the globe. Global measles deaths have decreased by 84% from an estimated 550,100 in 2000 to 89,780 in 2016.

    *Nearly 650 Million Vaccines Doses will be administered in Pediatrics (Infants) by the year 2024*

    It is estimated that by the year 2024, the doses of vaccines administered will reach nearly 650 Million. The number of vaccine doses is expected to grow considerably during the forecast period due to growing awareness among the parents about the benefits of vaccines and also the developing countries around the world that now have included a number of vaccines to their national immunization programme as per WHO recommendations, which indeed will drive the pediatric vaccine market in recent years.

    *Company Analysis:*

    GlaxoSmithKline, Merck, Sanofi, and Pfizer are some of the top companies that deal efficiently with vaccine business globally. These companies have been studied thoroughly in the report.*Key Topics Covered:**1. Research Findings*

    *2. Pediatric (Infant) Vaccines Market (2011 - 2024)*

    *3. Market & Numbers Share - Pediatric Vaccines*
    3.1 Pediatric Vaccine Market Share
    3.2 Pediatric Vaccinated Population Share
    3.3 Pediatric Doses of Vaccines Administered Share
    3.4 Vaccine Companies Market Share

    *4. Pediatric Vaccinated Numbers*

    *5. Pediatric Doses of Vaccines Administered*

    *6. Disease wise - Pediatric (Infants) Vaccines Market (2011 - 2024)*
    6.1 Influenza
    6.2 MMR (Measles, Mumps, and Rubella Vaccine)
    6.3 Pneumococcal
    6.4 Meningococcal
    6.5 Hepatitis
    6.6 DTaP
    6.7 Haemophilus Influenzae Type B (HIB)
    6.8 Combos (Combination)
    6.9 Polio
    6.10 Rotavirus
    6.11 Varicella

    *7. Disease wise - Numbers of Vaccinated Pediatric (Infants) (2011 - 2024)*
    7.1 Influenza
    7.2 MMR
    7.3 Pneumococcal
    7.4 Meningococcal
    7.5 Hepatitis
    7.6 DTaP
    7.7 Hib (Haemophilus Influenzae Type B)
    7.8 Combos (Combination Vaccines)
    7.9 Polio
    7.10 Rotavirus
    7.11 Varicella

    *8. Disease wise - Doses of Vaccines Administered in Pediatric (Infants) (2011 - 2024)*
    8.1 Influenza
    8.2 MMR
    8.3 Pneumococcal
    8.4 Meningococcal
    8.5 Hepatitis
    8.6 DTaP
    8.7 Hib (Haemophilus Influenzae Type B)
    8.8 Polio
    8.9 Rotavirus
    8.10 Varicella

    *9. Disease wise - Immunization Profile*
    9.1 Immunization Coverage (%) in Infants
    9.2 Global Immunization Profile
    9.3 Regional Immunization Profile
    9.3.1 Measles - Number of Reported Cases
    9.3.2 Mumps - Number of Reported Cases
    9.3.3 Rubella - Number of Reported Cases
    9.3.4 Rubella (CRS) - Number of Reported Cases
    9.3.5 Diphtheria - Number of Reported Cases
    9.3.6 Tetanus (Neonatal) - Number of Reported Cases
    9.3.7 Tetanus (Total) - Number of Reported Cases
    9.3.8 Pertussis - Number of Reported Cases
    9.3.9 Polio - Number of Reported Cases
    9.3.10 Yellow Fever - Number of Reported Cases
    9.3.11 Japanese encephalitis - Number of Reported Cases

    *10. Vaccines Key Players Sales (2011 - 2024)*
    10.1 GlaxoSmithKline, plc.'s Vaccines Sales
    10.2 Merck & Co. Vaccines Sales
    10.3 Sanofi Pasteur's Vaccines Sales
    10.4 Pfizer, Inc.'s Vaccines Sales
    10.5 Global - Other Companies Vaccines Sales

    *11. Vaccines - Products and Pipeline*
    11.1 GSK Vaccine Product Pipeline
    11.2 Merck Vaccine Product Pipeline
    11.3 Sanofi Vaccine Product Pipeline
    11.4 Pfizer Vaccine Product Pipeline

    *12. Top Mergers and Acquisitions in the Vaccine Industry*

    *13. Vaccines and Regulator's Interventions*
    13.1 Making and Meeting Standards of Quality and Safety
    13.2 Vaccine Funding

    *14. Vaccine Market Drivers*
    14.1 Inclusion in National Immunization Schedule
    14.2 Growing Immunization Coverage for HPV Vaccines
    14.3 Increase in Prevalence of Infectious Diseases
    14.4 Global Immunization Vision and Strategy (GIVS)
    14.5 GAVI Model Fuelling Vaccine Manufacturers
    14.5.1 The Partnership Model
    14.5.2 The Business Model
    14.6 Increasing Vaccine Availability in United States
    14.7 The Vaccine Safety Data link Project
    14.8 The Vaccine Injury Compensation Program
    14.9 Transforming of Vaccine Technologies
    14.10 Global Vaccine Action Plan by WHO (2011 - 2020)
    14.11 Continuous Focus on Effective Communication Strategies

    *15. Vaccines Market Challenges*
    15.1 Hurdles to Optimal use of Licensed Vaccines
    15.1.1 Technical Obstacles
    15.1.2 Economic Obstacles
    15.1.3 Cultural Obstacles
    15.2 Complexity of Vaccine Development & Approval System Thwarts Product Development
    15.2.1 Legal Obstacles
    15.2.2 General Technical Barriers
    15.2.3 Economic Barriers
    15.2.4 Regulatory Barriers
    15.3 Shortening the Timeline for Vaccine Development
    15.4 Refusal/Resistance to Vaccination
    15.4.1 Vaccine Adverse Event Reporting System
    15.5 Vaccine Shortages and Delays
    15.6 Obstacles in Vaccine Research & Development
    15.7 Barriers to New Entrants in the Vaccines Market*Companies Mentioned *· GlaxoSmithKline
    · Merck
    · Pfizer
    · Sanofi

    For more information about this report visit https://www.researchandmarkets.com/research/59p9vg/global_pediatric?w=12

    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

    CONTACT:
    CONTACT: ResearchAndMarkets.com
    Laura Wood, Senior Press Manager
    press@researchandmarkets.com
    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900
    Related Topics: Vaccines, Liver and Kidney Disorders Drugs , Pediatrics Reported by GlobeNewswire 10 hours ago.

    0 0

    Anyone who wants to enroll in the Affordable Care Act marketplace for health insurance in 2019 needs to do so by the end of the day Saturday, Dec. 15.

     
     
     
     
     
     
     
      Reported by azcentral.com 6 hours ago.

    0 0

    DC-based telecommunications company celebrates recognition for creating a positive, welcoming company culture with 2018 Best in Biz Awards win.

    Arlington, Virginia (PRWEB) December 13, 2018

    Allied Telecom Group has been named a silver winner for “Best Place to Work” in Best in Biz Awards, the only independent business awards program judged each year by prominent editors and reporters from top-tier publications in North America.

    Allied’s nomination was centered around recent enhancements to the company’s culture and benefits, often leveraging technology to facilitate new programs. In the past year, Allied launched a peer recognition tool that allows employees to send electronic “micro-bonuses” to one another, encouraging public recognition for great work, as well as an employee engagement tool that displays a company channel on screens throughout the office, and a performance management tool that automates and streamlines Allied’s employee review process. Additionally, Allied added several benefits to support employees’ health and wellness – including an HSA option with an employer contribution toward health insurance premiums. Aiming to compensate in the top quadrant of its industry, Allied also embarked upon an extensive salary benchmarking process in 2017, ensuring employees are compensated competitively relative to industry peers.

    Other company culture achievements highlighted in Allied’s Best in Biz nomination include a fully funded in-office Weight Watchers program to support employees seeking a healthier lifestyle. During the first twelve weeks of the program, participants collectively lost 268 pounds! Allied also initiated an annual “team appreciation” event in December, encouraging employees to publicly thank team members who supported them throughout the year.

    Each year, Best in Biz Awards’ entrants span the spectrum, from some of the most recognizable global brands to the most innovative local start-ups. The 8th annual program proved to be a particularly tough competition, garnering close to 700 entries from an impressive array of public and private companies of all sizes and from a variety of geographic regions and industries in the U.S. and Canada.

    “It’s so rewarding to see the efforts made by our leadership team and Human Resources department to improve Allied’s company culture recognized with a Silver award from Best in Biz Awards,” said Ashley Laporte, Allied’s Director of Human Resources. “Our people are our greatest asset, and we’ve worked hard to create benefits and implement programs that attract the top talent in the industry and to build a culture that keeps our team members happy and thriving at work.”

    Since 2011, winners in Best in Biz Awards have been determined based on scoring from independent judging panels deliberately composed each year of prominent editors and reporters from some of the most respected newspapers, TV outlets, and business, consumer, technology and trade publications in North America. Structured in this unique way, Best in Biz Awards is able to best leverage its distinguished judges’ unparalleled expertise, experience and objectivity to determine award winners from among the hundreds of entries. The 2018 judging panel included, among others, writers from Associated Press, Consumer Affairs, eWeek, Forbes, New York Post, New York Times, and Wired.

    For a full list of gold, silver and bronze winners in Best in Biz Awards 2018, visit: http://www.bestinbizawards.com/2018-winners.

    ABOUT ALLIED TELECOM: Allied is a highly regarded network service provider in the DC Metro, MidAtlantic and Northeast regions. Known best as a “trusted technology partner,” Allied has delivered Internet, data transport, voice, Unified Communications, and cloud connectivity solutions for clients in business, government and the nonprofit sector for more than 20 years. For more information, visit http://www.AlliedTelecom.net.

    ABOUT BEST IN BIZ AWARDS: Since 2011, Best in Biz Awards has made its mark as the only independent business awards program judged each year by a who’s who of prominent reporters and editors selected from top-tier publications from North America and around the world. Over the years, Best in Biz Awards judges have ranged from Associated Press to the Wall Street Journal and winners have spanned the spectrum, from blue-chip companies that form the bedrock of the world economy to local companies and some of the most innovative start-ups. For more information, visit: http://www.bestinbizawards.com. Reported by PRWeb 8 hours ago.

    0 0

    MIAMI, FL, Dec. 13, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Novus Acquisition and Development, Corp. (OTC Markets: NDEV), through its wholly owned subsidiary WCIG Insurance Services, Inc., is a diversified insurance entity in health, liability, annuity and accident, and, the nation’s first carrier/aggregator offering a cannabis health plan, today announced its plans to file as an Health Maintenance Organization (HMO) in the State of California.Novus Cannabis MedPlan had a positive initial teleconference with the California Department of Managed Health Care (CDMH) regarding filing its Cannabis MedPlan as a Health Maintenance Organization (HMO). Additional follow up reviews and evaluations by CDMH beginning as early as January 2019.

    Novus as an HMO will expand its breadth as health insurance carrier through its developed network of provider(s) such as:

    ·      Physicians (for example, family doctors that write cannabis recommendations),

    ·      Specialists (for example, oncologists and ophthalmologists that recommend cannabis) and,

    ·      Med facilities (for example, clinics and cannabis dispensaries/cultivators)

    Novus Cannabis MedPlan will initiate as an HMO where it will agree to pay cannabis providers specific levels of compensation for a range of services they provide to its patient/members commencing in the State of California. In return for a monthly fee, or premium, patient/members are granted access to providers inside Novus’ cannabis network at no additional cost.

    The value add of this premium structure is three-fold:

    ·      *Patients*: Reduce healthcare costs with likely reimbursement of cannabis meds and services for patient/members.

    ·      *Providers*: As an HMO cannabis network providers benefits by supplying them with more patients. 

    ·      *Employers*: Growing interest in Novus Cannabis MedPlan by many Professional Employment Organizations that want to integrate THC and CBD Plans for their client base in an HMO format. 

    Novus’ Chief Executive Officer Frank Labrozzi, stated, "This is an unprecedented opportunity for Novus and for the cannabis industry to be permitted by the CDMH to file as an HMO that includes cannabis as a benefits package. Since Novus announced it would begin its business model in an ever-evolving cannabis healthcare landscape, we believe we are seizing an opportunity by disrupting the old healthcare model that pits insurers against providers and instead of working directly with them to offer complete integrated care experience. Novus Cannabis MedPlan is the next generation of healthcare that will do away with the annoyance that many of us have experienced in getting traditional and cannabis related healthcare services.”

    As progress is made Novus will keep shareholders updated of its filing as it transpires.   

    *About Novus*

    Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has developed its infrastructure within many lines of the insurance business such as, health, property & casualty, life, accident and fixed annuities.

    Novus medical cannabis benefits package will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is competed the transaction is solely between the state-licensed dispensary and the registered patient.

    The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government's enforcement of current federal laws could cause significant financial changes to Novus Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a change in enforcement by federal or state governments.

    ·      For more information, please visit: https://bit.ly/2u1NgMh

    ·      For NDEV Financial Filing: https://www.otcmarkets.com/stock/NDEV/filings

    ·      Learn How Insurance Companies Are Evaluated: http://bit.ly/2ddIYva

    *Forward-Looking Statements*

    This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Novus disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    CONTACT: Contact Information

    Corporate:

    Chairman and CEO

    Frank Labrozzi

    frank@ndev.biz

    855-228-7355

     

    Investors:

    Hayden IR

    hart@haydenir.com

    917-658-7878 Reported by GlobeNewswire 8 hours ago.

older | 1 | .... | 940 | 941 | (Page 942) | 943 | 944 | .... | 952 | newer